Varian places RT units; offers storage system

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Members agreed that perioperative regimen NSCLC trial designs should clarify the contribution of treatment during adjuvant and neoadjuvant therapy.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD

July 22nd 2024

Creating Confidence While Climbing the Ranks in the Lymphoma Field

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Ariana Pelosci

Overcoming Physical and Social Barriers in the Lymphoma Field

“Sometimes you have to be a little more assertive and a little louder, and you have to step up to the front,” Julie M. Vose, MD, MBA, said.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Julie M. Vose, MD, MBA;Avyakta Kallam, MD

July 15th 2024

Novel CAR T-Cell Therapy Receives FDA RMAT Status in Advanced Thyroid Cancer

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

$Results from a phase 1 trial evaluating the CAR T-cell therapy, AIC100, in relapsed/refractory thyroid cancer support the FDA’s RMAT designation.$

Roman Fabbricatore

FDA Accepts Resubmitted BLA for Remestemcel-L in Pediatric SR-aGVHD

Results from a phase 1 trial evaluating the CAR T-cell therapy, AIC100, in relapsed/refractory thyroid cancer support the FDA’s RMAT designation.

The agency has set a Prescription Drug User Fee Act date of January 7, 2025, for its decision on approving remestemcel-L in this patient population.

ODAC Votes in Favor of New Perioperative NSCLC Trial Design Proposals

The agency has set a Prescription Drug User Fee Act date of January 7, 2025, for its decision on approving remestemcel-L in this patient population.

Related Content

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Members agreed that perioperative regimen NSCLC trial designs should clarify the contribution of treatment during adjuvant and neoadjuvant therapy.

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD

July 22nd 2024

Creating Confidence While Climbing the Ranks in the Lymphoma Field

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Ariana Pelosci

Overcoming Physical and Social Barriers in the Lymphoma Field

“Sometimes you have to be a little more assertive and a little louder, and you have to step up to the front,” Julie M. Vose, MD, MBA, said.

Julie M. Vose, MD, MBA;Avyakta Kallam, MD

July 15th 2024

Novel CAR T-Cell Therapy Receives FDA RMAT Status in Advanced Thyroid Cancer

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

$Results from a phase 1 trial evaluating the CAR T-cell therapy, AIC100, in relapsed/refractory thyroid cancer support the FDA’s RMAT designation.$

Roman Fabbricatore

FDA Accepts Resubmitted BLA for Remestemcel-L in Pediatric SR-aGVHD

Results from a phase 1 trial evaluating the CAR T-cell therapy, AIC100, in relapsed/refractory thyroid cancer support the FDA’s RMAT designation.